Please indicate your specialization * - Select -GastroenterologistHepatologistSurgeons (transplant and Hep/Onc)OncologistGI/oncology nurseGI/oncology physician assistantGI/oncology nurse practitionerRadiologistPathologistClinical/biomedical researcher in molecular oncology Please select the country in which you live: * United States Canada Europe Other, please specify: Please select the country in which you live: Other, please specify: What is your preferred method for online learning about recent advances in predictive biomarkers for cancer immunotherapy? * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congresses highlights Interactive E-learning modules Infographics/visual summaries Other, please specify: What is your preferred method for online learning about recent advances in predictive biomarkers for cancer immunotherapy? Other, please specify: If you are not able to attend a congress how do you get updated on the information presented there? * Online written congress reports Online expert roundtable congress reports Local/regional meetings with experts that attended the congress Other, please specify: If you are not able to attend a congress how do you get updated on the information presented there? Other, please specify: How aware are you of the current recommendations for the use of predictive biomarkers for cancer immunotherapy? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you with the different types of emerging biomarkers being investigated for predicting response to immune checkpoint inhibitors? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How informed are you about the emerging tumor mutational burden (TMB) biomarker being investigated for predicting sensitivity to immune checkpoint inhibitors? * Very well informed Well informed Reasonably informed Poorly informed Not informed How informed are you about the emerging mismatch repair (MMR) or microsatellite instability (MI) biomarker being investigated for predicting sensitivity to immune checkpoint inhibitors? * Very well informed Well informed Reasonably informed Poorly informed Not informed How informed are you about what the different biomarkers measure (PD-L1 IHC, TMB, MMR/MI) and their significance? * Very well informed Well informed Reasonably informed Poorly informed Not informed How informed are you about the different next-generation sequencing technology platforms and comprehensive gene panels that are currently being used in immune-oncology research? * Very well informed Well informed Reasonably informed Poorly informed Not informed What is your preferred method for online learning about recent advances in the management of hepatocellular carcinoma? * Scientific publications Roundtable/panel discussions by experts in the field Case studies presented by experts in the field Webcasts by experts in the field International congresses highlights Interactive E-learning modules Infographics/visual summaries Other, please specify: What is your preferred method for online learning about recent advances in the management of hepatocellular carcinoma? Other, please specify: If you are not able to attend a congress how do you get updated on the information presented there? * Online written congress reports Online expert roundtable congress reports Local/regional meetings with experts that attended the congress Other, please specify: If you are not able to attend a congress how do you get updated on the information presented there? Other, please specify: How aware are you of the current treatment options for patients with advanced hepatocellular carcinoma? * Very aware Aware Reasonably aware Not very aware Not aware How familiar are you with the different mechanisms of cancer immune escape in hepatocellular carcinoma? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How informed are you about the mechanism of action of emerging immunotherapies for patients with advanced hepatocellular carcinoma? * Very well informed Well informed Reasonably informed Poorly informed Not informed How informed are you about the latest clinical trial data on emerging targeted therapies for advanced hepatocellular carcinoma? * Very well informed Well informed Reasonably informed Poorly informed Not informed How informed are you about the latest clinical trial data on emerging immunotherapies for patients with advanced hepatocellular carcinoma? * Very well informed Well informed Reasonably informed Poorly informed Not informed How familiar are you with the difference in the safety profiles between current treatment options, emerging targeted therapies and emerging immunotherapies for patients with advanced hepatocellular carcinoma? * Very familiar Familiar Reasonably familiar Not very familiar Not familiar How aware are you of the combination therapies that are being investigated in advanced hepatocellular carcinoma? * Very aware Aware Reasonably aware Not very aware Not aware If you are interested in participating in the raffle for a $100/€100 Amazon gift card, please fill out the following: First Name: Last Name: Email: Leave this field blank
